natgillin/translations-raw huggingface dataset:
M Lead the needle tip into the big outer needle cap without touching the big outer needle cap.
M Konico igle vstavite v veliki zunanji pokrov ek igle, ne da bi se ga dotaknili.
Dispose of it carefully and put the pen cap back on.
Pazljivo jo zavrzite in na peresnik znova namestite njegov pokrov ek.
M
99 M
• Always remove the needle after each injection and store your FlexPen without the needle attached.
• Po vsakem injiciranju morate iglo odstraniti in zavre i, FlexPen pa shraniti brez nameš ene igle.
NovoMix 50 FlexPen 100 U/ ml suspension for injection in a pre-filled pen Insulin aspart
NovoMix 50 FlexPen 100 e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku insulin aspart
1.
Na tej strani 1.
What NovoMix 50 is and what it is used for 2.
Kaj je zdravilo NovoMix 50 in za kaj ga uporabljamo 2.
Before you use NovoMix 50 3.
Kaj morate vedeti, preden boste uporabili zdravilo NovoMix 50 3.
How to use NovoMix 50 4.
Kako uporabljati zdravilo NovoMix 50 4.
How to store NovoMix 50 7 Further information
Dodatne informacije
It comes in a 3 ml pre-filled pen, called FlexPen - see overleaf for detailed instructions.
Na voljo je v 3- ml napolnjenem injekcijskem peresniku, imenovanem FlexPen – za podrobna navodila glejte hrbtno stran tega navodila za uporabo.
Consult your doctor if you are planning such travelling.
Vaša potreba po insulinu se lahko spremeni. e imate okužbo, zvišano telesno temperaturo ali ste bili operirani, lahko potrebujete ve 101 insulina kot obi ajno. e imate drisko, bruhate ali jeste manj kot sicer, lahko potrebujete manj insulina kot obi ajno. e potujete v tujino: potovanje med razli nimi asovnimi pasovi lahko vpliva na potrebe po insulinu in asovni razpored injekcij. e na rtujete tako potovanje, se posvetujte s svojim zdravnikom.
Check the label to make sure it is the right type of insulin Always use a new needle for each injection to prevent contamination.
Za vsako injiciranje uporabite novo iglo, da prepre ite kontaminacijo
NovoMix 50 should not be used
Shranjevanje zdravila NovoMix 50), e insulin po mešanju ni enakomerno bel in moten, e so v njem vidne grude ali se dna ali stene vložka držijo trdni beli delci, podobni ivju.
If your blood sugar gets too high
103 e se vam sladkor v krvi preve zviša
Swollen joints.
104 Otekli sklepi.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.
e kateri koli neželeni u inek postane resen ali e opazite kateri koli neželen u inek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika, diabetološko sestro ali farmacevta.
NovoMix 50 FlexPen that is not being used is to be stored in the refrigerator (2°C – 8°C), not in or to near the freezer section or cooling element.
Zdravilo NovoMix 50 FlexPen, ki ni v uporabi, shranjujte v hladilniku (2 °C - 8 °C), ne v zamrzovalniku in ne preblizu zamrzovalnika ali hladilnega elementa.
NovoMix 50 FlexPen that is being used or about to be used is not to be kept in the refrigerator.
Peresnika NovoMix 50 FlexPen, ki ga uporabljate ali ga boste pravkar uporabili, ne shranjujte v hladilniku!
Getting started.
Kako uporabljati zdravilo NovoMix 50.
NovoMix 50 FlexPen must be protected from excessive heat and sunlight.
Zdravilo NovoMix 50 FlexPen je treba zaš ititi pred ezmerno toploto in son no svetlobo.
– The active substance is insulin aspart made by recombinant DNA technology in Saccharomyces cerevisiae (50% insulin aspart in a soluble fraction and 50% insulin aspart crystallised with protamine) – The other ingredients are glycerol, phenol, metacresol, zinc (as chloride), sodium chloride, disodium phosphate dihydrate, protamine sulphate, sodium hydroxide, hydrochloric acid and water for injections.
Pomožne snovi so glicerol, fenol, metakrezol, cink (kot klorid), natrijev klorid, natrijev – hidrogenfosfat dihidrat, protaminijev sulfat, natrijev hidroksid, klorovodikova kislina in voda za injekcije.
What NovoMix 50 looks like and contents of the pack The suspension for injection comes as a white suspension in packs of 1, 5 or 10 pre-filled pens of 3 ml (not all packs may be marketed).
Izgled zdravila NovoMix 50 in vsebina pakiranja Suspenzija za injiciranje je bela suspenzija, ki je na voljo v pakiranjih z 1, 5 ali 10 napolnjenimi 3- ml injekcijskimi peresniki (na trgu morda ni vseh navedenih pakiranj).
105 Introduction
105 Uvod
Please read the following instructions carefully before using your NovoMix 50 FlexPen.
Preden uporabite NovoMix 50 FlexPen, natan no preberite ta navodila
NovoMix 50 FlexPen Pen cap
NovoMix 50 FlexPen pokrov ek peresnika
12 Glass
12 steklena
units ball
enot kroglica
scale
prostanka
needle cap needle cap
pokrov ek igle
tab
pokrov ek igle
Preparing your NovoMix 50 FlexPen
Priprava peresnika NovoMix 50 FlexPen
This makes it easier to resuspend.
A Preden insulin uporabite, ga pustite, da doseže sobno temperaturo.
106 Pull off the pen cap.
106 Tako ga boste lažje resuspendirali.
If the moving procedure alone is not enough to give a uniformly white and cloudy liquid, repeat the rolling and moving procedures (see B and C) until the liquid does appear uniformly white and cloudy
Za vsako naslednje injiciranje obrnite peresnik z vložkom vsaj desetkrat gor in dol med obema položajema, dokler ni teko ina enakomerno bela in motna. e s tem postopkom ne dobite enakomerno bele in motne teko ine, ga ponavljajte (glejte B in C), dokler ni teko ina enakomerno bela in motna.
107 D
107 D
108 Hold your FlexPen with the needle pointing upwards and tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge.
108 H Držite FlexPen tako, da je igla obrnjena navzgor, in s prstom nekajkrat rahlo potrkajte po vložku, da se bodo morebitni zra ni mehur ki zbrali na vrhu vložka.
109 J
109 J
110 M
110 M
NovoMix 70 FlexPen 100 U/ ml suspension for injection in a pre-filled pen Insulin aspart
NovoMix 70 FlexPen 100 e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku insulin aspart
What NovoMix 70 is and what it is used for 2.
Kaj je zdravilo NovoMix 70 in za kaj ga uporabljamo 2.
Before you use NovoMix 70 3.
Kaj morate vedeti, preden boste uporabili zdravilo NovoMix 70 3.
How to use NovoMix 70 4.
Kako uporabljati zdravilo NovoMix 70 4.
How to store NovoMix 70 7 Further information
Dodatne informacije
Your need for insulin may change If you have an infection, fever or have had an operation you may need more insulin than usual
e imate težave z ledvicami ali jetri, se lahko vaš zdravnik odlo i prilagoditi vaš odmerek insulina. e pijete alkohol (tudi pivo in vino): pazite na znake hipe in alkohola nikdar ne pijte na prazen želodec. e ste telesno bolj dejavni kot ponavadi ali želite spremeniti svojo obi ajno prehrano. e ste bolni: insulin uporabljajte še naprej.
Consult your doctor if you are planning such travelling.
Vaša potreba po insulinu se lahko spremeni. e imate okužbo, zvišano telesno temperaturo ali ste bili operirani, lahko potrebujete ve 112 insulina kot obi ajno. e imate drisko, bruhate ali jeste manj kot sicer, lahko potrebujete manj insulina kot obi ajno. e potujete v tujino: potovanje med razli nimi asovnimi pasovi lahko vpliva na potrebe po insulinu in asovni razpored injekcij. e na rtujete tako potovanje, se posvetujte s svojim zdravnikom.
NovoMix 70 should not be used
Shranjevanje zdravila NovoMix 70), e po mešanju ni enakomerno bel in moten, e so v njem vidne grude ali se dna ali stene vložka držijo trdni beli delci, podobni ivju.
WHAT TO DO IN AN EMERGENCY
4 UKREPANJE V NUJNIH PRIMERIH
If your blood sugar gets too high
114 e se vam sladkor v krvi preve zviša
Seek medical advice immediately: • If signs of allergy spread to other parts of your body, or • If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heart beat; feel dizzy.
Nemudoma poiš ite zdravniško pomo, e: se znaki alergije razširijo na druge dele telesa ali • se nenadoma slabo po utite in se: za nete znojiti, vam postane slabo (bruhate), težko dihate, • vam srce hitro bije, ste omoti ni.
Swollen joints.
115 Otekli sklepi.
115 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.
e kateri koli neželeni u inek postane resen ali e opazite kateri koli neželen u inek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika, diabetološko sestro ali farmacevta.
NovoMix 70 FlexPen that is not being used is to be stored in the refrigerator (2°C – 8°C), not in or to near the freezer section or cooling element.
Zdravilo NovoMix 70 FlexPen, ki ni v uporabi, shranjujte v hladilniku (2 °C - 8 °C), ne v zamrzovalniku in ne preblizu zamrzovalnika ali hladilnega elementa.
NovoMix 70 FlexPen that is being used or about to be used is not to be kept in the refrigerator.
Peresnika NovoMix 70 FlexPen, ki ga uporabljate ali ga boste pravkar uporabili, ne shranjujte v hladilniku!
Getting Started.
Kako uporabljati zdravilo NovoMix 70.
NovoMix 70 FlexPen must be protected from excessive heat and sunlight.
Zdravilo NovoMix 70 FlexPen je treba zaš ititi pred ezmerno toploto in son no svetlobo.
What NovoMix 70 looks like and contents of the pack The suspension for injection comes as a white suspension in packs of 1, 5 or 10 pre-filled pens of 3 ml (not all packs may be marketed).
Izgled zdravila NovoMix 70 in vsebina pakiranja Suspenzija za injiciranje je bela suspenzija, ki je na voljo v pakiranjih z 1, 5 ali 10 napolnjenimi 3- ml injekcijskimi peresniki (na trgu morda ni vseh navedenih pakiranj).
116 Introduction
116 Zdaj na hrbtni strani preberite, kako uporabljati FlexPen.
Please read the following instructions carefully before using your NovoMix 70 FlexPen.
Preden uporabite NovoMix 70 FlexPen, natan no preberite ta navodila
NovoMix 70 FlexPen Pen cap
NovoMix 70 FlexPen pokrov ek peresnika
12 Glass Cartridge Residual
12 steklena vložek
Preparing your NovoMix 70 FlexPen
Priprava peresnika NovoMix 70 FlexPen
117 Pull off the pen cap.
117 A Preden insulin uporabite, ga pustite, da doseže sobno temperaturo.
D Remove the protective tab from a new disposable needle.
D
118 D
118 Odstranite zaš itno nalepko z nove igle za enkratno uporabo.
119 Hold your FlexPen with the needle pointing upwards and tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge.
119 H Držite FlexPen tako, da je igla obrnjena navzgor, in s prstom nekajkrat rahlo potrkajte po vložku, da se bodo morebitni zra ni mehur ki zbrali na vrhu vložka.
120 J
120 J
121 M
121 M
It is available as round tablets (white:
Na voljo je v obliki okroglih tablet (bele:
0.5 mg; yellow:
0, 5 mg; rumene:
1 mg; peach:
1 mg; barve breskve:
A doctor should regularly test the patient ’ s blood glucose to find the lowest effective dose.
Zdravnik mora redno preverjati bolnikovo glukozo v krvi, da določi najmanjši učinkoviti odmerek.
The recommended starting dose is 0.5 mg.
Priporočeni začetni odmerek je 0, 5 mg.
It should also not be used in patients with type 1 (insulin-dependent) diabetes who do not have any ‘ C-peptide ’ in their blood (a marker of type 1 diabetes).
Prav tako ga ne smejo uporabljati bolniki s sladkorno boleznijo tipa 1 (od insulina odvisno sladkorno bolezen), ki nimajo nobenega C- peptida v krvi (označevalca sladkorne bolezni tipa 1).
The Committee for Medicinal Products for Human Use (CHMP) decided that NovoNorm’ s benefits are greater than its risks for the treatment of type 2 diabetes.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila NovoNorm za zdravljenje sladkorne bolezni tipa 2 večje od z njim povezanih tveganj.
The European Commission granted a marketing authorisation valid throughout the European Union for NovoNorm to Novo Nordisk A/ S on 17 August 1998.
Evropska komisija je dovoljenje za promet z zdravilom NovoNorm, veljavno po vsej Evropski uniji, odobrila družbi Novo Nordisk A/ S dne 17. avgusta 1998.
NovoNorm 0.5 mg tablets
NovoNorm 0, 5 mg tablete
Each tablet contains 0.5 mg of repaglinide.
Ena tableta vsebuje 0, 5 mg repaglinida.
Repaglinide tablets are white, round and convex and engraved with Novo Nordisk logo (Apis bull).
Tablete repaglinida so bele, okrogle, izbočene in imajo vrezan logo družbe Novo Nordisk (bika Apisa).
Repaglinide is indicated in patients with type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
Repaglinid je indiciran pri bolnikih z diabetesom tipa 2 (diabetesom mellitusom, ki ni odvisen od insulina), pri katerih hiperglikemije ni več mogoče zadovoljivo obvladovati z dieto, zmanjšanjem telesne mase in telesno dejavnostjo.
Repaglinide is also indicated in combination with metformin in type 2 diabetes patients who are not satisfactorily controlled on metformin alone.
Repaglinid je indiciran tudi v kombinaciji z metforminom pri bolnikih z diabetesom tipa 2, ki niso zadovoljivo urejeni samo z metforminom.
In addition to the usual self-monitoring by the patient of blood and/ or urinary glucose, the patient ’ s blood glucose must be monitored periodically by the physician to determine the minimum effective dose for the patient.
Poleg običajne samokontrole glukoze v krvi in/ ali urinu, ki jo izvaja bolnik, mora bolnikovo glukozo v krvi redno nadzirati tudi zdravnik, da določi za bolnika najmanjši učinkoviti odmerek.
Glycosylated haemoglobin levels are also of value in monitoring the patient’ s response to therapy.
Za spremljanje bolnikovega odziva na zdravljenje je pomembna tudi koncentracija glikiranega hemoglobina.
Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i. e. primary failure) and to detect loss of adequate blood glucose- lowering response after an initial period of effectiveness (i. e. secondary failure).
Redno spremljanje je potrebno, da bi odkrili nezadostno znižanje glukoze v krvi ob priporočenem največjem odmerku (tj. primarno odpoved), ali nezadostno znižanje glukoze po uvodnem obdobju učinkovitosti (tj. sekundarno odpoved).
Short-term administration of repaglinide may be sufficient during periods of transient loss of control in type 2 diabetic patients usually controlled well on diet.
Kratkotrajna uporaba repaglinida lahko zadošča v obdobjih prehodne izgube nadzora nad diabetesom tipa 2 pri bolnikih, pri katerih je bolezen ponavadi dobro urejena z dieto.
Repaglinide should be taken before main meals (i. e. preprandially).
Repaglinid je treba jemati pred glavnimi obroki (tj. predprandialno).
Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal (i. e. preprandially 2, 3, or 4 meals a day).
Odmerek se običajno vzame 15 minut pred obrokom, vendar lahko čas zaužitja sega od 30 minut pred obrokom do tik pred njim (tj. predprandialno, 2, 3 ali 4 obroki na dan).
Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Bolniku morate naročiti naj v primeru, da izpusti (ali zaužije dodaten) obrok, izpusti (ali doda) odmerek za tisti obrok.
In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage.
V primeru sočasne uporabe z drugimi zdravilnimi učinkovinami glejte poglavji 4. 4 in 4. 5 za oceno odmerjanja.
Initial dose The dosage should be determined by the physician, according to the patient’ s requirements.
Začetni odmerek Odmerek mora določiti zdravnik glede na bolnikove potrebe.
If patients are transferred from another oral hypoglycaemic agent the recommended starting dose is
2 Če bolnik preide na repaglinid z drugega peroralnega antidiabetika, je priporočeni začetni odmerek repaglinida 1 mg.
Maintenance The recommended maximum single dose is 4 mg taken with main meals.
Vzdrževanje Priporočeni največji posamični odmerek repaglinida je 4 mg ob glavnih obrokih.
Specific patient groups Repaglinide is primarily excreted via the bile and excretion is therefore not affected by renal disorders.
Specifične skupine bolnikov Repaglinid se primarno izloča z žolčem, zato bolezni ledvic ne vplivajo na izločanje.
No clinical studies have been conducted in patients > 75 years of age or in patients with hepatic insufficiency (see section 4.4).
Pri bolnikih, starejših od 75 let, in bolnikih z jetrno insuficienco ni bilo kliničnih študij (glejte poglavje 4. 4).
Repaglinide is not recommended for use in children below age 18 due to a lack of data on safety and/ or efficacy.
Uporaba repaglinida ni priporočljiva pri otrocih, mlajših od 18 let, zaradi pomanjkanja podatkov o varnosti in/ ali učinkovitosti.
In debilitated or malnourished patients the initial and maintenance dosage should be conservative and careful dose titration is required to avoid hypoglycaemic reactions.
Pri oslabelih in podhranjenih bolnikih mora biti začetno in vzdrževalno odmerjanje konzervativno; odmerek je treba skrbno titrirati, da bi preprečili hipoglikemične reakcije.
Patients receiving other oral hypoglycaemic agents (OHAs) Patients can be transferred directly from other oral hypoglycaemic agents to repaglinide.
Bolniki, ki dobivajo druge peroralne antidiabetike Bolnike je mogoče na repaglinid prevesti neposredno z drugih peroralnih antidiabetikov.
However, no exact dosage relationship exists between repaglinide and the other oral hypoglycaemic agents.
Vendar pa med odmerjanjem repaglinida in drugih peroralnih antidiabetikov ni natančnega razmerja.
The starting dose of repaglinide is 0.5 mg, taken before main meals; titration is according to blood glucose response as for monotherapy.
Začetni odmerek repaglinida je 0, 5 mg pred glavnimi obroki; prilagajanje poteka glede na odziv glukoze v krvi, tako kot pri monoterapiji.
IDDM), C-peptide negative • Diabetic ketoacidosis, with or without coma • Severe hepatic function disorder • Concomitant use of gemfibrozil (see section 4.5).
• Preobčutljivost za repaglinid ali katero koli pomožno snov v zdravilu NovoNorm. • Diabetes tipa 1 (od insulina odvisni diabetes mellitus), C- peptid negativni. • Diabetična ketoacidoza s komo ali brez nje. • Hudo moteno delovanje jeter. • Sočasna uporaba gemfibrozila (glejte poglavje 4. 5).
General Repaglinide should only be prescribed if poor blood glucose control and symptoms of diabetes persist despite adequate attempts at dieting, exercise and weight reduction.
Splošno Repaglinid se sme predpisati le, če se slaba urejenost glukoze v krvi in simptomi diabetesa nadaljujejo kljub ustrezni dieti, telesni dejavnosti in zmanjšanju telesne mase.
Repaglinide like other insulin secretagogues, is capable of producing hypoglycaemia.
Tako kot drugi sekretagogi insulina lahko tudi repaglinid povzroči hipoglikemijo.
The blood glucose-lowering effect of oral hypoglycaemic agents decreases in many patients over time.
Učinkovitost zniževanja glukoze v krvi s peroralnimi antidiabetiki se pri mnogih bolnikih sčasoma zmanjša.
This may be due to progression of the severity of the diabetes or to diminished responsiveness to the product.
To je morda posledica napredovanja diabetesa ali zmanjšane odzivnosti na zdravilo.
This phenomenon is known as secondary failure, to distinguish it from primary failure, where the drug is ineffective in an individual patient when first given.
Pojav je poznan kot sekundarna odpoved, za razliko od primarne odpovedi, pri kateri je zdravilo neučinkovito, že ko ga posameznik dobi prvič.
Repaglinide acts through a distinct binding site with a short action on the β -cells.
Repaglinid deluje prek posebnega vezavnega mesta s kratkim delovanjem na celice β.
3 performed.
3 Preskušanj, ki bi proučila kombinacijo z drugimi sekretagogi insulina in z akarbozo, ni bilo.
However, the benefit risk profile remains to be established when comparing to other combination therapies.
Preskušanja s kombiniranim zdravljenjem z NPH (Neutral Protamin Hagedorn) insulinom ali tiazolidindioni so bila izvedena, vendar je treba značilnosti glede koristi in tveganja še ugotoviti v primerjavi z drugimi kombiniranimi zdravljenji.
When a patient stabilised on any oral hypoglycaemic agent is exposed to stress such as fever, trauma, infection or surgery, a loss of glycaemic control may occur.
Dejavniki stresa, npr. zvišana telesna temperatura, poškodba, okužba ali operacija, lahko pri bolnikih, katerih stanje je s katerim od peroralnih antidiabetikov stabilno, povzročijo izgubo urejenosti glukoze v krvi.
At such times, it may be necessary to discontinue repaglinide and treat with insulin on a temporary basis.
V takšnih primerih utegne biti potrebna prekinitev repaglinida in prehodno zdravljenje z insulinom.
The use of repaglinide might be associated with an increased incidence of acute coronary syndrome (e. g. myocardial infarction) (see sections 4.8 and 5.1).
Uporabo repaglinida lahko spremlja večja pogostnost akutnega koronarnega sindroma (npr. miokardni infarkt) (glejte poglavji 4. 8 in 5. 1).
Concomitant use Repaglinide should be used with caution or be avoided in patients receiving drugs which influence repaglinide metabolism (see section 4.5).
Sočasna uporaba drugih zdravil Pri bolnikih, ki dobivajo zdravila z vplivom na presnovo repaglinida, morate repaglinid uporabiti previdno ali se mu izogniti (glejte poglavje 4. 5).
If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed.
Če je sočasna uporaba obeh zdravil nujna, je potrebno pazljivo spremljati vrednosti krvne glukoze in bolnika natančno klinično spremljati.
Specific patient groups No clinical studies have been conducted in patients with impaired hepatic function.
Specifične skupine bolnikov Pri bolnikih z okvarjenim delovanjem jeter ni bilo kliničnih študij.
No clinical studies have been performed in children and adolescents < 18 years of age or in patients > 75 years of age.
Pri otrocih, mladostnikih do 18. leta in bolnikih, starejših od 75 let, ni bilo kliničnih študij.
Therefore, treatment is not recommended in these patient groups.
Zato teh skupin bolnikov ni priporočljivo zdraviti z repaglinidom.
Careful dose titration is recommended in debilitated or malnourished patients.
Pri oslabelih ali podhranjenih bolnikih je priporočljivo pazljivo prilagajanje odmerka.
The initial and maintenance dosages should be conservative (see section 4.2).
Začetni in vzdrževalni odmerek morata biti previdno odmerjena (glejte poglavje 4. 2).
Possible interactions should therefore be taken into account by the physician:
Na presnovo repaglinida lahko vplivajo številna zdravila, zato mora zdravnik upoštevati možne interakcije:
In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4.
Podatki in vitro raziskav nakazujejo, da se repaglinid metabolizira pretežno s CYP2C8, vendar tudi s CYP3A4.
Clinical data in healthy volunteers support CYP2C8 as being the most important enzyme involved in repaglinide metabolism with CYP3A4 playing a minor role, but the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited.
Klinični podatki pridobljeni na zdravih prostovoljcih potrjujejo domnevo, da je CYP2C8 najbolj pomemben encim pri metabolizmu repaglinida in da ima CYP3A4 manjšo vlogo, vendar pa se relativen prispevek CYP3A4 lahko poveča, kadar je CYP2C8 inhibiran.
Consequently metabolism, and by that clearance of repaglinide, may be altered by drugs which influence these cytochrome P-450 enzymes via inhibition or induction.
Zato se metabolizem in s tem tudi očistek repaglinida lahko spremenita zaradi zdravil, ki vplivajo na te citokrom P- 450 encime bodisi z inhibicijo ali indukcijo.
Special care should be taken when both inhibitors of CYP2C8 and 3A4 are co- administered simultaneously with repaglinide.
Posebna previdnost je potrebna v primerih istočasne aplikacije obeh zaviralcev CYP2C8 in 3A4 hkrati z repaglinidom.
Drugs that inhibit OATP1B1 may likewise have the potential to increase plasma concentrations of repaglinide, as has been shown for ciclosporin (see below).
Zdravila, ki zavirajo OATP1B1, lahko morda koncentracijo repaglinida v plazmi zvišajo podobno, kot je ugotovljeno za ciklosporin (glejte spodaj).